Aquestive Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€37.87M - Cost of goods sold
€14.73M - Gross profit
€23.13M - SG&A expenses
€51.40M - R&D expenses
€16.86M - EBITDA
-€38.39M - D&A
€2.86M - EBIT
-€45.13M - Interest expenses
€14.57M - EBT
-€55.82M - Tax expenses
-€12.01K - Net income
-€55.81M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€6.99M - Changes in working capital
€1.18M - Operating cash flow
-€42.63M - Capex
€289.15K - Other investing cash flow
€0.00 - Net investing cash flow
-€289.15K - Total cash dividends paid
€0.00 - Issuance of common stock
€18.36M - Debt repayment
-€18.02K - Other financing cash flow
-€585.16K - Net financing cash flow
€17.75M - Foreign exchange effects
€0.00 - Net change in cash
-€25.17M - Cash at end of period
€51.94M - Free cash flow
-€42.34M
Balance sheet
- Cash and cash equivalents
€51.94M - Cash and short-term investments
€51.94M - Total receivables
€10.18M - Inventory
€6.97M - Other current assets
€1.03M - Total current assets
€70.12M - Property, plant & equipment
€7.52M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€1.72M - Other non-current assets
€1.04M - Total non-current assets
€10.28M - Total assets
€80.39M - Accounts payable
€10.25M - Short-term debt
€4.39M - Other current liabilities
€4.29M - Total current liabilities
€19.87M - Long-term debt
€103.94M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€1.76M - Total non-current liabilities
€122.81M - Total liabilities
€142.68M - Common stock
€84.94K - Retained earnings
-€342.94M - Other equity
€0.00 - Total equity
-€62.28M - Total liabilities and shareholders' equity
€80.39M
Company information
- Market capitalization
€275.35M - Employees
142 - Enterprise Value
€309.19M
Company ratios
- Gross margin
-
61.1% Much better than peer group: 28.5% - EBITDA margin
-
-101.4% Much worse than peer group: 939,327.9% - EBIT margin
-
-119.2% Much worse than peer group: 884,540.2% - EBT margin
-
-147.4% Much worse than peer group: 939,731.8% - Net margin
-
-147.4% Much worse than peer group: 851,999.8% - ROE
-
89.6% Much better than peer group: -38.8% - ROA
-
-69.4% Much worse than peer group: -48.0% - Asset turnover
-
47.1% Even with peer group: 51.4% - FCF margin
-
-113.3% Much worse than peer group: 660,856.7% - FCF yield
-15.6% - Efficiency ratio
201.4% - Net sales per employee
-
€266.66K - Net income per employee
-
-€393.00K